Clinical Investigation of the Rex Medical -Closer™ Vascul... | NCT01873898

NCT01873898

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Single Arm	Experimental	This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.	Device: Rex Medical Closer™ Vascular Closure System

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Rex Medical Closer™ Vascular Closure System	Device	The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Time to Ambulation	Time to Ambulation - in minutes, defined as the time from when hemostasis is achieved to the time when ambulation is achieved (patient standing and walking at least 6.1 meters [20 feet] without re-bleeding).	Day 0
Frequency of Major Adverse Events through 30 days	The primary safety endpoint is the frequency of Major Adverse Events through 30 days, defined as one of the following events related to the use of the investigational device: a hematoma requiring a transfusion, a device embolization, false aneurysm requiring intervention or a retroperitoneal bleed.	30 days

Secondary Outcomes

Measure	Description	Time Frame
Time to Hemostasis	Time to Hemostasis - in minutes, defined as the time from when the delivery system releases both sutures, which are attached to the sealing member, to the time that hemostasis (absence of expanding or developing hematoma) is achieved	Day 0
Placement Technical Success

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Subject is > 18 years of age.
Subject is able to undergo diagnostic angiography procedure and is found suitable to receive such a device at the femoral arterial puncture site in order to reduce time to hemostasis.
Subject or his/her legal guardian understands the nature of the procedure, and provides written informed consent prior to the procedure.
Subject is available and willing to participate in follow-up through 30 days post femoral closure.

Exclusion Criteria:

Subject with known allergies to polylactic acid (PLA), polyglycolic acid (PGA) or polydioxanone (PDO) polymers
Subject with severe acute non-cardiac systemic disease
Subject with evidence of systemic infection
Subject where bacterial contamination of the procedural sheath or surrounding tissues may have occurred as this may increase risk of infection
Subject with coagulopathy (bleeding disorders, including thrombocytopenia, hemophilia, etc.)
Subject taking thrombolytic medication which reduces fibrinogen to less than 100 mg/dl
Subject who has had a previous arterial access in the femoral artery on the treatment side with an existing hematoma >5 cm in diameter
Subject who is unable to ambulate at baseline
Subject who has had another closure device used in the treatment side within the previous 90 days
Subject who requires re-entry of the treatment side planned within the next 90 days post-procedure
Subject has a history of surgical repair on the treatment side
Subject has planned surgeries for any reason within 90 days post- procedure
Subject is pregnant or is lactating (non-pregnancy must be confirmed by testing)
Has a history of a psychiatric condition, substance abuse or alcohol abuse that, in the opinion of the investigator, will potentially interfere with his or her participation
Subject has been previously enrolled in the Rex Closer™ study
Subject who is currently or within the previous 4 weeks been enrolled in another investigational device or drug trial
Subject is incarcerated at the time of enrollment
Subject where the procedural sheath has been placed through the superficial femoral artery and into the profundafemoris
Subject where the procedure puncture site is at or distal to the bifurcation of the superficial femoral profundafemoris artery, as this may result in 1) the intravascular sealing patch catching on the bifurcation or being positioned incorrectly, and/or 2) intravascular deployment of the device into the vessel (These events may reduce blood flow through the vessel leading to symptoms of distal arterial insufficiency.)
Subject's procedure was accessed through a vascular graft
Subjects with uncontrolled hypertension (> 230 mm Hg systolic)
Subjects with small femoral artery size (Less than 5 mm in diameter)
Subjects with stenosis > 50% at the vicinity of the femoral arterial puncture site
Subjects with anomalous branches or vessel abnormalities present in the vicinity of the femoral arterial puncture site

ID	Term
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms